
Skinvive Injectable Review: Cost, Results, and More
I've tried every face mist, buttery moisturizer, and hydrating serum out there. And while skincare definitely helps support my skin barrier and offers temporary relief, it's not a heal-all solution for the chronic dryness I've endured my entire life. So when I heard about Skinvive, an injectable moisturizer that's basically like a supercharged hydrator in a syringe, I was immediately intrugued. As a filler/botox/injectable virgin, I was a bit hesitant about the treatment. But after years of dealing with dry skin, I was ready to try anything.
Keep reading for everything you need to know about Skinvive, including what it is, how much it costs, what results to expect, and my honest experience four months post-treatment. Plus, I tapped expert insight from plastic surgeon David Shafer, MD, for his insights too.
Skinvive is the first FDA-approved hyaluronic acid microdroplet injectable. For your skin, it works to improve hydration from within, as well as smooth skin texture and increase luminosity.
'Skinvive is injected right underneath the top layer of the skin to act as an instant hydrator," says Dr. Shafer. It's injected into several spots across your cheeks in a grid-like pattern using a tiny needle. 'It upregulates the aquaporin channels, which are the connections between cells that help promote water and moisture balance in the skin, creating a more hydrated, moisture-rich environment,' he explains.
While Skinvive is packed with hyaluronic acid for hydration, it goes beyond just quenching dry skin. 'Skinvive helps reduce fine lines and wrinkles, improves texture, and gives the skin a smoother, more luminous appearance,' says Dr. Shafer. After one session of Skinvive, patients can expect the following results:
I personally noticed the hydration benefit more than anything else (though I'm not exactly the target demographic for fine lines just yet). Not only is my skin no longer overly dry or tight, but I also don't need to use as much moisturizer or serum as I used to. Plus, my makeup goes on way smoother thanks to my plump and hydrated face.
It takes about three to four weeks to see the full effects of Skinvive. 'You're waiting for that hydration to kick in via the boost of those aquaporin channels,' says Dr. Shafer. 'Once it starts working, the effects can last a good three to six months.'
It wasn't something I noticed overnight, but about a month after my treatment, I thought to myself wait, my skin hasn't flaked or itched in weeks.
Yes, Skinvive is perfectly safe to get alongside Botox and fillers. 'It's a natural add-on for patients already getting injectables,' says Dr. Shafer. 'It's not a filler, and it's not Botox—it's a whole new category of treatment. It's an injectable skin hydrator.'
One isn't necessarily better than the other, they're just different. 'They both involve injections, but filler adds volume and structure to the skin, while Skinvive adds hydration,' explains Dr. Shafer. The treatment process is similar, but the effects serve different skin goals. If you want to combat dryness, Skinvive is the best option here.
Price: Skinvive injections start at around $750 per treatment. It's definitely not a budget-friendly alternative to moisturizer, but the cost is on par with many traditional filler and injectable appointments.
Soreness: I felt some discomfort during the treatment, but I had numbing cream on, so it was tolerable. As someone who's never had anything injected into their face (and who's even scared of flu shots), the anxiety leading up to my appointment was worse than the actual pain. The treatment itself took less than ten minutes, and the only side effects I experienced were some swelling and tenderness on my cheeks for about a day following.
Overall, Skinvive is definitely worth it if you have super dry skin that no moisturizer or product can fully quench, especially in the winter months. If you're on the oilier side, it's not a must-have, but it could be a nice way to support and hydrate your skin barrier from the inside, without needing to layer on extra creams, serums, and moisturizers.
It's also been a surprising win for my acne-prone skin. Since I'm not loading up on as many hydrating products, I've noticed fewer breakouts overall. Looking back at old selfies, my skin was definitely more congested and I broke out more frequently before Skinvive. Plus, it's a really nice skin-smoother if you're dealing with uneven texture or fine lines.
Jasmine Hyman is the assistant beauty editor at Cosmopolitan, where she covers everything in the skincare space from sunscreen to serums. For this story, she got a Skinvive treatment to see the results first-hand, and also spoke with Dr. Shafer for all his insight on the injection.
Jasmine Hyman is the Assistant Beauty Editor at Cosmopolitan, where she writes about the latest beauty trends and must-have products. Her most prized beauty possessions are a meticulous skincare routine and salon blowouts. You'll also likely find her in bed reading a good book or endlessly scrolling TikTok (spoiler: it's usually the latter) while listening to Harry Styles' entire discography on repeat. Follow her on Insta to be inundated with pictures of her meals.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial
The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group's investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the trial will focus on supporting prolonged heart perfusion leveraging the OCS Heart System. OCS Heart comprises a portable, warm perfusion system, which is said to maintain a donor heart in a metabolically active state, allowing physicians to monitor and assess the heart's condition and viability. Part B aims to demonstrate the OCS Heart perfusion's superiority in donation after brain death (DBD) cases over traditional static cold storage methods. This part is aimed at supporting the potential expansion of the system use for DBD hearts, which are currently ineligible for OCS perfusion and preservation. The anticipated sample size for both parts of the trial is set to exceed 650 subjects, which the company believes would make the largest heart preservation for transplant trial ever worldwide. TransMedics Group CEO and president Waleed Hassanein said: "The recent FDA approvals to initiate our Next-Gen OCS ENHANCE Heart and DENOVO Lung trials mark key milestones in our ongoing commitment to transforming the standard of care and addressing the major clinical needs of the cardiothoracic transplant community. "We are thrilled to be in a position to initiate both trials in the fourth quarter of 2025 while we continue to work collaboratively with the FDA to address any remaining questions related to pre-clinical testing. 'As I have stated before, we hope these two trials will be major catalysts for clinical adoption for both heart and lung throughout 2026 and beyond." In 2023, the company completed the acquisition of a premier US charter flight operator, Summit Aviation. This move has established TransMedics Aviation as the first dedicated national air logistics provider exclusively for organ transplantation in the US. "FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Connectez-vous pour accéder à votre portefeuille
Yahoo
8 hours ago
- Yahoo
You're Ruining Your Gains If You Skip These 8 Recovery Foods
You're Ruining Your Gains If You Skip These 8 Recovery Foods originally appeared on Men's Fitness. Men's Fitness aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. After an intense workout, the body needs to repair damaged muscle tissue. Pick the right food and you can jump-start that recovery process without ruining the gains you made in the gym. Amino acids—the building blocks of protein—are essential to bolstering recovery. And to ensure you get adequate amino acids, you need to eat protein. Your body also needs glycogen, found in carb-rich foods, since stores gets depleted during training. Eating a combo of protein and carbs is key to workout recovery, and foods that are good sources of both should become staples in your diet. Add these eight healthy eats to your diet to maximize recovery after a workout. Best Post-Workout Recovery Foods Lean Meat Although our bodies produce non-essential amino acids, we also need essential amino acids, ones that are not made in the body and must be consumed from our diets. One of the best sources of essential amino acids is lean meat such as chicken, turkey, and ground beef. According to the FDA, a 'lean' meat contains less than 10 grams of fat, 4.5 grams or less of saturated fat, and less than 95 milligrams of cholesterol per 100 grams. Choose meats that are at least 90 percent lean to ensure you're not getting too much saturated fat and cholesterol. Quinoa One cup of cooked quinoa contains about 8 grams of protein and 40 grams of carbohydrates, making it a nutrient-packed post-workout dish. Unlike other grains, quinoa is a complete protein since it contains all nine essential amino acids, which results in better muscle recovery and more energy. Plain Greek Yogurt Greek yogurt has 15 to 20 grams of protein per 6 ounces compared to 9 grams of protein in an identical serving of regular yogurt. The protein in Greek yogurt is predominantly casein, which digests slower than whey and boasts a full essential amino acid profile. Opt for plain Greek yogurt since it has substantially less sugar than flavored Greek yogurt. To really capitalize on the benefits of casein, eat it before bedtime for extended amino acid digestion. Smoothies Smoothies make a great post-workout recovery drink because of the instant absorption of a custom assortment of nutrients. Just be mindful of how much sugar you add—piling on the fruit can quickly turn a post-workout "nutrition shake" into a secret sugar bomb. Bananas Nature designed the humble banana to be a post-workout recovery machine. One serving includes about 27 grams of carbohydrates, an essential energy resource to ignite your body's muscle repair systems. Additionally, a potassium-packed banana replenishes the depleted electrolyte stores in your muscles, reducing soreness and speeding up the recovery process. The best part is that bananas are naturally sweet, which means it's an ideal addition to a post-workout protein shake or smoothie without adding any refined sugar. Low-fat Chocolate Milk The perfect recovery ratio of carbohydrates to protein is 4:1, according to a growing collection of studies. Chocolate milk matches this ratio better than any sugary sports drink, turning the lunch box staple into a powerful recovery option. A study from Applied Physiology, Nutrition, and Metabolism also found exercisers are able to retain more than twice the amount of fluid in chocolate milk than in a sports drink after a workout, meaning the body is able to absorb more protein with less volume. Avocados Bananas get all the attention when it comes to potassium, but avocados actually have an average of 35 percent more per serving. The fruit is also full of monosaturated fats, which have been linked to reducing cholesterol levels. With an additional 3 grams of protein, vital for muscle growth, the avocado is a filling addition to a post-workout meal. Sweet Potatoes Another potassium powerhouse, the sweet potato contains 448 milligrams in one serving. Because of its orange hue it also comes packed with carotenoids—compounds that aid cell repair, which is vital during the recovery process after a workout. The starchy carbs from sweet potatoes also help restock energy stores, while the fiber will keep you full and encourage you not to spring for something less healthy later in the Ruining Your Gains If You Skip These 8 Recovery Foods first appeared on Men's Fitness on Aug 1, 2025 This story was originally reported by Men's Fitness on Aug 1, 2025, where it first appeared. Solve the daily Crossword
Yahoo
11 hours ago
- Yahoo
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist. IBI3032 is an orally administered small-molecule GLP-1 receptor agonist with bias for cAMP signaling pathway, discovered and developed by Innovent Biologics with proprietary rights. Preclinical data demonstrate its superior pharmacokinetic (PK) and physicochemical properties compared to peer compounds. In animal models, IBI3032 achieved 5 to 10 times higher oral exposure at equivalent doses, with improved efficacy and good tolerability in both GLP-1R KI DIO mice and obese monkey models, achieving comparable therapeutic effects at lower doses. The Phase 1 clinical trials of IBI3032 are planned to be conducted concurrently in China and the U.S. Dosing in healthy volunteers and overweight or obese participants is expected to begin in the second half of 2025. Innovent is building up its CVM pipeline with mazdutide as the cornerstone, and the initiation of the IBI3032 clinical study marks a significant step in the evolution of its CVM pipeline portfolio with global potential. Dr. Lei Qian, Chief R&D Officer for General Biomedicines Pipeline at Innovent Biologics, said, "GLP-1 has emerged as a blockbuster target over the past decade. Its oral form, with its convenience, flexibility, and unique advantage in combination treatment strategies, holds promise as a differentiated complement to GLP-1R-targeting biologicals. Beyond traditional applications in diabetes and weight management, oral GLP-1 possess potential in treating related diseases such as hypertension and OSA (obstructive sleep apnea). IBI3032 has demonstrated its promising efficacy profiles in animal models, where IBI3032 exhibited a longer elimination half-life and higher drug exposure levels than its competitors at the same dose. We are excited to advance this candidate into clinical development. This IND approval reflects Innovent's strong R&D capabilities and, most importantly, our commitment to global innovation. We hope that in the near future, IBI3032 can offer more effective and convenient treatment options to benefit patients around the world. " About IBI3032 IBI3032 is a novel oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA). By efficiently and selectively targeting GLP-1R, it activates downstream signal transduction, thereby delaying gastric emptying, inhibiting appetite, and promoting insulin secretion, and ultimately supporting the treatment of insulin-related metabolic diseases such as obesity and T2DB. Discovered through a structure-based drug design (SBDD) strategy combined with systematic physicochemical property optimization, IBI3032 has shown better PK and physicochemical properties compared to similar compounds. The IND application of IBI3032 was accepted by China's National Medical Products Administration (NMPA) and approved by the U.S. Food and Drug Administration (FDA). A multi-regional Phase 1 clinical study of IBI3032 is planned for initiation in the second half of 2025. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s). (2)Ramucirumab (Cyramza),Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data